| Active substance | Momelotinib |
| Holder | GlaxoSmithKline Pharmaceuticals S.A./N.V. |
| Status | Running |
| Indication | the treatment of disease related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or who have been treated with ruxolitinib. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 07/02/2024 |